Sirt6 Signaling As An Underexplored Mechanistic Node In Nanoformulation-Based Neuroinflammation Therapy For Alzheimer’S Disease
Alzheimer’s disease is characterized by chronic brain inflammation, a key driver of its progression. Recent research has explored using tiny, specially designed particles, called nanomodulators, to deliver therapies directly to inflammatory brain cells, known as microglia. One such nanomodulator has shown promise by both dampening inflammatory signals and boosting the brain’s natural antioxidant defenses in these cells. However, the precise mechanism connecting these two beneficial actions remained unclear. This perspective suggests that a protein called sirtuin 6 (SIRT6) could be the missing link. SIRT6 acts like a master switch, capable of turning down inflammatory pathways (specifically, NF-κB signaling) and, at the same time, activating pathways that protect cells from damage by increasing antioxidant production (NRF2-dependent defense). The decline of SIRT6 in the aging brain is associated with DNA damage and other hallmarks of Alzheimer’s. By targeting SIRT6 specifically within microglia using nanoformulations, researchers hope to achieve these dual therapeutic effects while minimizing potential side effects that might arise from activating SIRT6 throughout the body. This hypothesis provides a new direction for understanding and potentially treating Alzheimer’s-related neuroinflammation.
Source: link to paper